secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2024-09-03T23:59:59+00:00
Accession:  0001493152-24-034729
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma effects 1:50 reverse stock split; trading halted on NYSE American, risk of delisting
--------------------------------------------------------------------------------

- Effective Aug 30, 2024, Matinas executed a 1:50 reverse stock split and reduced authorized shares from 500M to 250M.
- Trading of MTNB halted on NYSE American on Aug 27 due to low price; expects to resume split-adjusted on Sep 3 subject to exchange approval.
- If post-split share price fails to meet NYSE American requirements, exchange could suspend trading or delist the stock.
- No fractional shares issued; stockholders with fractional entitlements were rounded up to the next whole share.
- Reverse split approved by stockholders on Nov 1, 2023; Board authorized filing on Aug 20, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315224034729/0001493152-24-034729-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315224034729/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-034729

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer